DURHAM, N.C. - Humacyte, Inc. (NASDAQ:HUMA), a biotechnology platform company, announced positive outcomes from its V007 Phase 3 clinical trial of the acellular tissue engineered vessel (ATEV) for arteriovenous (AV) access in patients with end-stage renal disease. The results were presented at the American Society of Nephrology's Kidney Week 2024.
The trial compared ATEV to the current standard of care, autogenous fistula, in hemodialysis access. ATEV showed superior function and patency at six and 12 months, the co-primary endpoints of the study. Notably, ATEV demonstrated better outcomes in female, obese, and diabetic patients—subgroups that traditionally have poorer results with autogenous fistula procedures.
On Saturday, Dr. Mohamad A. Hussain highlighted the significant extension of access duration over one year in these high-need groups, potentially reducing catheter reliance for AV access. The trial enrolled 242 U.S. patients, with results showing 81.3% functional patency at six months and 68.3% at 12 months for ATEV recipients, versus 66.4% and 62.2% for those with AV fistulas, respectively.
Sub-group analysis revealed that female patients with ATEV had significantly higher patency rates and longer hemodialysis duration over 12 months compared to those with AV fistula. Similarly, obese and diabetic patients also benefited from ATEV with higher patency rates and longer hemodialysis duration than their counterparts receiving AV fistulas.
The ATEV and AV fistula groups had low infection rates, with 9.1% and 9.9% of patients experiencing access-related infections, respectively. However, thrombosis was more common in the ATEV group, with 52.1% of patients affected, although 94% of these cases were successfully treated.
Humacyte's ATEV is still under investigation and awaits FDA approval. The company is known for developing implantable bioengineered human tissues for various medical applications, with several ATEVs in late-stage clinical trials for different vascular uses.
The information in this article is based on a press release statement from Humacyte, Inc.
In other recent news, Humacyte, a biotech company, has been the subject of several significant developments. The firm reported a net loss of $56.7 million for a recent quarter while simultaneously raising approximately $30 million through a registered direct offering of common stock and warrants. Humacyte's Acute Tissue Engineered Vascular (ATEV) product has shown promising results in Phase 3 trials, but the FDA review for vascular trauma has been postponed. Furthermore, the company has been granted a U.S. Patent for its BioVascular Pancreas (BVP), a device aimed at treating type 1 diabetes.
TD Cowen, EF Hutton, and Benchmark have all maintained a Buy rating on Humacyte, with respective price targets of $10, $25, and $15. On the other hand, Piper Sandler and BTIG have reiterated their neutral stance and Buy rating respectively. These firms believe that issues raised by the FDA in a Form 483 observation have been or can be resolved by Humacyte.
Lastly, Humacyte reported positive long-term results from a humanitarian program using its ATEV to treat severe vascular injuries in a military setting. These updates are part of the recent developments that may be of interest to investors in Humacyte.
InvestingPro Insights
As Humacyte, Inc. (NASDAQ:HUMA) reports positive outcomes from its Phase 3 clinical trial, investors may be interested in additional financial insights. According to InvestingPro data, Humacyte's market capitalization stands at $698.93 million, reflecting the market's current valuation of the company's potential.
InvestingPro Tips highlight that Humacyte holds more cash than debt on its balance sheet, which could provide financial flexibility as the company progresses through its clinical trials and potential FDA approval process. This strong liquidity position is further supported by the fact that the company's liquid assets exceed its short-term obligations.
Despite the promising clinical results, it's important to note that Humacyte is not currently profitable. An InvestingPro Tip indicates that analysts do not anticipate the company will be profitable this year, which is not unusual for biotechnology companies in the development stage. However, investors have shown enthusiasm for Humacyte's potential, as evidenced by the significant price uptick over the last six months, with a 40.1% price total return in that period.
The company's stock has demonstrated remarkable performance, with a one-year price total return of 178.11% as of the latest data. This aligns with the positive clinical trial results and may reflect investor optimism about Humacyte's ATEV technology.
For those interested in a deeper analysis, InvestingPro offers 10 additional tips for Humacyte, providing a more comprehensive view of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.